Development of CP506 a novel hypoxia-selective cytotoxin for the treatment of triple negative breast cancer (TNBC)

dc.contributor.advisor	Abbattista, M	en
dc.contributor.advisor	Patterson, A	en
dc.contributor.advisor	Guise, C	en
dc.contributor.author	Moore, Sarah	en
dc.date.accessioned	2019-11-20T22:37:13Z	en
dc.date.issued	2019	en
dc.identifier.uri	http://hdl.handle.net/2292/48966	en
dc.description	Thesis embargoed until 11/2021.	en
dc.publisher	ResearchSpace@Auckland	en
dc.relation.ispartof	Masters Thesis - University of Auckland	en
dc.relation.isreferencedby	UoA99265329914102091	en
dc.rights	Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher.	en
dc.rights	Restricted Item. Full Text is available to authenticated members of The University of Auckland only.	en
dc.rights	Restricted Item. Thesis embargoed until 11/2021. Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated.	en
dc.rights.uri	https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm	en
dc.title	Development of CP506 a novel hypoxia-selective cytotoxin for the treatment of triple negative breast cancer (TNBC)	en
dc.type	Thesis	en
thesis.degree.discipline	Biomedical Science	en
thesis.degree.grantor	The University of Auckland	en
thesis.degree.level	Masters	en
dc.rights.holder	Copyright: The author	en
dc.rights.accessrights	http://purl.org/eprint/accessRights/ClosedAccess	en
pubs.elements-id	786514	en
pubs.record-created-at-source-date	2019-11-21	en

Files in this item